Evidence map›Paper›PMID 28460462›Full record

ArticleOncotarget2017

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.

Nora Ness, Sigve Andersen, Mehrdad Rakaee Khanehkenari, Cecilie V Nordbakken, Andrej Valkov, Erna-Elise Paulsen, Yngve Nordby, Roy M Bremnes, Tom Donnem, Lill-Tove Busund and 1 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 7 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 7 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nora NessDepartment of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Sigve AndersenDepartment of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Mehrdad Rakaee KhanehkenariDepartment of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Cecilie V NordbakkenDepartment of Clinical Pathology, University Hospital of North Norway, N-9038 Tromso, Norway.
Andrej ValkovDepartment of Clinical Pathology, University Hospital of North Norway, N-9038 Tromso, Norway.
Erna-Elise PaulsenDepartment of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Yngve NordbyDepartment of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Roy M BremnesDepartment of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Tom DonnemDepartment of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Lill-Tove BusundDepartment of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
Elin RichardsenDepartment of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
UiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors. PD-L1 expression was commonly seen in tumor epithelial cells (92% of cases). Univariate survival analysis revealed a positive association between a high density of PD-1+ lymphocytes and worse clinical failure-free survival, limited to a trend (p = 0.084). In subgroups known to indicate unfavorable prostate cancer prognosis (Gleason grade 9, age < 65, preoperative PSA > 10, pT3) patients with high density of PD-1+ lymphocytes had a significantly higher risk of clinical failure (p = < 0.001, p = 0.025, p = 0.039 and p = 0.011, respectively). In the multivariate analysis, high density of PD-1+ lymphocytes was a significant negative independent prognostic factor for clinical failure-free survival (HR = 2.48, CI 95% 1.12-5.48, p = 0.025).

Indexed as

Biomarkers, TumorImmunomodulationAgedAged, 80 and overB7-H1 AntigenCancer-Associated FibroblastsHumansImmunohistochemistryImmunophenotypingLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorB7-H1 AntigenBiomarkers, TumorCD274 protein, humanProgrammed Cell Death 1 ReceptorimmunohistochemistryPD-1PDL-1prognostic markerprostate cancer

Identifiers

PMID28460462
PMCPMC5432297
OpenAlexW2591840592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.